GlassScriptPhysician profile
Holly Henderson
NPI 1710034954
$3,619.08
in general payments reported to CMS, 2019-2025
28 companies · $1,207 in 2025
The $1,207 reported for 2025 was more than what 89% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $55.64 · 2022: $53.17 · 2023: $1,210 · 2024: $1,093 · 2025: $1,207.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,510.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,510.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $794.81 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $505.38 | 2023-2025 | Airsupra, Breztri, Farxiga |
| Otsuka America Pharmaceutical, INC. | $372.23 | 2023-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Novo Nordisk INC | $315.52 | 2023-2025 | Ozempic, Wegovy, Rybelsus |
| Novartis Pharmaceuticals Corporation | $249.25 | 2021-2025 | |
| Medtronic, INC. | $220.89 | 2023-2024 | Corevalve Evolut R |
| Axsome Therapeutics, INC. | $165.35 | 2023-2025 | Auvelity |
| Amgen INC. | $122.59 | 2024-2025 | Evenity, Prolia, Otezla |
| Gilead Sciences, INC. | $104.29 | 2023 | Epclusa |
| Lilly USA, LLC | $84.28 | 2023-2025 | Mounjaro, Zepbound, Trulicity |
| Teva Pharmaceuticals USA, INC. | $77.26 | 2023-2025 | Austedo Xr, Austedo Xr |
| Edwards Lifesciences Corporation | $76.64 | 2023 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Boehringer Ingelheim Pharmaceuticals, INC. | $72.90 | 2024-2025 | Jardiance |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $59.80 | 2025 | Caplyta |
| Lundbeck LLC | $55.70 | 2024-2025 | Rexulti |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $54.08 | 2023 | Erleada |
| Exact Sciences Corporation | $41.30 | 2024 | Cologuard Collection Kit |
| Pfizer INC. | $31.71 | 2025 | |
| Xeris Pharmaceuticals, INC. | $31.49 | 2024-2025 | Gvoke Hypopen |
| Corium, LLC | $29.98 | 2023 | Azstarys |
| Sumitomo Pharma America, INC. | $24.88 | 2023 | Gemtesa |
| Vanda Pharmaceuticals INC. | $21.89 | 2025 | Fanapt |
| Bayer Healthcare Pharmaceuticals INC. | $20.92 | 2022 | |
| Bard Access Systems, INC. | $19.35 | 2021 | |
| Vertex Pharmaceuticals Incorporated | $18.56 | 2025 | |
| Harmony Biosciences LLC | $17.06 | 2023 | Wakix |
| Mylan Specialty L.P. | $16.21 | 2024 | Yupelri |
| Takeda Pharmaceuticals U.S.A., INC. | $14.76 | 2025 | Trintellix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Holly Henderson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.